AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
EPCLUSA has 2.8 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: EPCLUSA (epclusa.com)
EPCLUSA provides a highly coherent, patient-focused narrative that is low on typical ‘corporate synergy’ BS but high on pharmaceutical gatekeeping. It successfully avoids semantic drift but fails technically on authority through a total absence of structured data and external evidence paths. It is a well-designed marketing tool that prioritizes convenience claims over clinical transparency.
Implement MedicalWebPage and Organization schema_json to establish technical authority and link to the parent company’s sameAs profiles. Replace redundant H6 ‘Find confidence’ tags with specific H2/H3 headings citing clinical trial cure rates (e.g., ‘98% Cure Rate in Clinical Trials’). Add a dedicated ‘Clinical Evidence’ section to the Why Epclusa page with direct outbound links to published peer-reviewed studies on PubMed. Ensure all H1 tags are populated with the specific drug name and primary indication to fix the broken heading hierarchy.
The site exhibits high information density for a patient-facing pharma site. Headings like ‘One pill, once a day, for 12 weeks’ and ‘sofosbuvir/velpatasvir’ contain specific nouns and numbers rather than pure fluff. However, soft power words like ‘Find confidence’ and ‘Your To-Day List’ appear in H4 and H6 tags, creating a moderate fluff saturation of approximately 30%. The body substance ratio is strong due to technical mentions of medication-assisted treatments like buprenorphine/naloxone and naltrexone.
When your heading hierarchy collapses, AI cannot determine where one idea ends and the next begins. Run a Semantic HTML Machine Readability Audit to see how your structure is actually chunked by LLMs.
There is zero semantic drift across the analyzed pages. The homepage promise of curing Hep C ‘your way’ is directly supported by sub-pages explaining the regimen’s compatibility with recovery and medication-assisted treatments. The messaging is highly consistent, focusing on the patient’s schedule and lifestyle across all sub-pages, with no contradictions between the ‘Helpful Resources’ and the ‘Why Epclusa’ value propositions.
Identify the current state and friction diagnosis of your specific business model. Generate your Executive SEO Strategy to quantify the financial or conversion cost of strategic misalignment.
The site suffers from trust theatre through omission; despite a review_count of 0 and a proof_links_count of 0 in the data, the site makes bold medical claims such as ‘Cure Hep C.’ While FDA approval is claimed in H5, the lack of direct outbound links to clinical studies or a Specificity ID on the evaluated pages represents a reliance on brand authority rather than forensic evidence. This triggers the trust theatre penalty because medical efficacy is asserted without a verification path provided in the data.
The ratio of evidence to assertions is mixed. Verifiable proof regarding usage (3 years of age and older, 12 weeks) is high. However, the density of external verification (outbound links to peer-reviewed studies or clinical trial registries) is 0 according to the proof_links_count. The site relies entirely on its status as a prescription medication for trust rather than providing open-access proof density.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The site uses standard pharmaceutical template fingerprints including ‘Patient Resources,’ ‘Financial Resources,’ and ‘Find a healthcare provider.’ Clichés like ‘One step closer to cure’ and ‘Where science meets compassion’ are present, though the latter is implied through the recovery-focused narrative. The value proposition is somewhat unique due to its specific targeting of patients in recovery, but the technical structure is a copy-paste of a standard drug-branded microsite.
A significant authority gap exists in the technical implementation: the schema_json is null across all pages, which is a failure for a high-stakes medical brand in 2026. There is no Person schema for clinical leads and no Organization schema to establish institutional weight. While the brand itself is the authority, the digital footprint lacks the structured data required to support an ‘industry leader’ claim forensicly.
The marketing tone ‘Treat hepatitis C your way’ is backed by the physical demonstration of ‘one pill in a regular pill bottle small enough to fit in your pocket.’ However, the disconnect lies in the high-stakes claim of ‘Curing Hep C’ without providing direct access to the clinical trial data that proves it. The site functions as a patient brochure rather than a clinical evidence repository, which creates a transparency gap.
Medical Devices, Pharma & Biotech BS: EPCLUSA (epclusa.com)
The content perfectly aligns with the Pharmaceutical and Biotech industry. It focuses on a specific therapeutic area (Hepatitis C), mentions specific drug components (sofosbuvir/velpatasvir), and adheres to regulatory-mandated safety information and indications for use.
A page that loads perfectly for users can still return an empty shell to an AI crawler. Examine the Crawlability Technical Guide and understand why script free extraction is the real measure of visibility.
“The score of 38 reflects a site that is medically substantial but technically weak in the Authority and Trust pillars. The Information Density and Semantic Coherence pillars performed exceptionally well, preventing a higher BS score. The lack of schema and external proof paths are the primary drivers of the final score.”